Inactive Instrument

AVEO Pharmaceuticals, Inc.

AVEO

US0535883070

AVEO Pharmaceuticals : to Present at the 33rd Annual J.P. Morgan Healthcare Conference

January 12, 2015 at 06:31 am EST

AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 33^rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 12:00PM (PT) in San Francisco.

A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at aveooncology.com. A replay of the webcast will be archived for 90 days following the presentation date.

About AVEO

AVEO Oncology (NASDAQ:AVEO) is a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide substantial improvements in patient outcomes where significant unmet medical needs exist. AVEO’s proprietary Human Response Platform™ has delivered unique insights into cancer and related disease biology that are being leveraged in the clinical development of its therapeutic candidates. For more information, please visit the company’s website at www.aveooncology.com.

Latest news about AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals, Inc. Announces Executive Changes	Mar. 25	CI
Aveo Oncology Announces Publication of Long-Term Survival in Patients with Relapsed/Refractory Advanced Renal Cell Carcinoma Treated with Tivozanib: Analysis of the Phase Iii Tivo-3 Trial in the Oncologist	Feb. 06	CI
AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)	Jan. 16	CI
AVEO Oncology Announces Completion of Enrollment in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA(R) in Combination with OPDIVO(R) in Advanced Renal Cell Carcinoma	23-06-27	CI
South Korean Stocks Climb on Demand Recovery Hopes from China; LG Chem Stocks Add 1%	23-01-20	MT
AVEO Completes Acquisition by LG Chem	23-01-20	MT
LG Chem Acquires US Biopharma Firm AVEO Pharmaceuticals	23-01-19	MT
AVEO Pharmaceuticals, Inc. Announces Management Changes	23-01-19	CI
AVEO Oncology Appoints Martin Birkhofer as Its Chief Medical Officer	23-01-19	CI
AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from NASDAQ Composite Index	23-01-19	CI
AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P Global BMI Index	23-01-19	CI
AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P TMI Index	23-01-19	CI
LG Chem, Ltd. completed the acquisition of AVEO Pharmaceuticals, Inc. from a group of shareholders.	23-01-18	CI
AVEO Pharmaceuticals Receives CFIUS Clearance for LG Chem Merger	23-01-18	MT
AVEO Pharmaceuticals Stockholders Approve LG Chem Merger	23-01-06	MT
North American Morning Briefing : Midterm Outcome -3-	22-11-09	DJ
Stifel Downgrades AVEO Pharmaceuticals to Hold From Buy, Price Target is $15	22-11-08	MT
Earnings Flash (AVEO) AVEO PHARMACEUTICALS Reports Q3 Revenue $30.4M, vs. Street Est of $29.9M	22-11-07	MT
AVEO Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-07	CI
Aveo Pharmaceuticals, Inc. Withdraws Earnings Guidance for the Year 2022	22-11-07	CI
JonesTrading Downgrades AVEO Pharmaceuticals to Hold From Buy With $15 Price Target	22-10-31	MT
SVB Securities Downgrades AVEO Pharmaceuticals to Market Perform From Outperform, Retains Price Target at $15	22-10-24	MT
South Korea's Kospi, Kosdaq Decline Ahead of Earnings Season; LG Chem Sheds 3%	22-10-19	MT
LG Chem to Acquire AVEO Pharmaceuticals for $566 Million	22-10-19	MT
Baird Downgrades AVEO Pharmaceuticals to Neutral From Outperform, Adjusts Price Target to $15 From $17	22-10-19	MT

Chart AVEO Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

AVEO Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is focused on delivering medicines for patients with cancer. The Company's commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The Company markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. It also develops FOTIVDA in immuno-oncology combinations in refractory RCC and other indications and has several other investigational programs in clinical development. The Company's pipeline of product candidates includes ficlatuzumab, AV-380, AV-203 and AV-353. Its ficlatuzumab is a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF).

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-5.99%	84.46B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.85B
BIOGEN INC.	-25.67%	27.69B
UCB	+53.61%	24.28B
BIOMARIN PHARMACEUTICAL INC.	-7.91%	17.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-33.74%	13.67B
INCYTE CORPORATION	-16.34%	11.86B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.19%	11.79B
SWEDISH ORPHAN BIOVITRUM AB	-2.25%	8.07B

Biopharmaceuticals